Advanced Drug Delivery Reviews is a peer-reviewed review journal of Elsevier, founded in 1987 and indexed in the Science Citation Index Expanded with a 2025 Impact Factor of 21.0Advanced Drug Delivery Reviews 是 Elsevier 旗下的同行评审综述期刊，创刊于 1987 年，被科学引文索引扩展版收录，2025 年影响因子为 21.0。
Critical reviews of advanced drug and gene delivery systems and their applications in medicine发表对先进药物与基因递送系统及其医学应用的批判性综述。
Coverage of nanomedicine, polymer therapeutics, liposomes, and targeted drug delivery涵盖纳米医学、高分子治疗、脂质体与靶向药物递送。
Studies on drug delivery to specific organs, tumors, and intracellular targets研究向特定器官、肿瘤与细胞内靶点的药物递送。
Articles on the formulation, biopharmaceutics, and pharmacokinetics of delivery systems刊载关于递送系统的制剂、生物药剂学与药代动力学的文章。
Reviews that bridge delivery science with clinical translation and therapeutic outcomes发表将递送科学与临床转化及治疗结局相联系的综述。
The journal was founded in 1987 as a review-focused title in pharmaceutical science该刊于 1987 年创刊，是药学领域专注于综述的期刊。
It is published by Elsevier and currently releases fifteen issues per year由 Elsevier 出版，目前每年发行 15 期。
Over decades it has become one of the most highly cited journals in pharmacology and pharmacy数十年来，该刊已成为药理学与药学领域被引频次最高的期刊之一。
It has consistently ranked in the first quartile of the Pharmacology and Pharmacy category该刊持续在药理学与药学分类中位列一区。
Editor-in-Chief is María J. Vicent of the Príncipe Felipe Research Center, Spain主编为西班牙 Príncipe Felipe 研究中心的 María J. Vicent。
Executive editors assist the EiC in managing reviews and special issues执行编辑协助主编管理综述稿件与专题。
The editorial board includes leading scientists in drug delivery and nanomedicine编委会由药物递送与纳米医学领域的顶尖科学家组成。
Authors may choose open access publication through Elsevier's hybrid open access option作者可通过 Elsevier 的混合型开放获取选项发表开放获取论文。